AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-137047765/biogen-fda-pitch-ms.html" title="Facts and information about Biogen's FDA Pitch For MS Treatment Might Be Long Shot But It's Worth It, Execs Say The company breaks from tradition in attempt to get Tysabri back on the market.(HEALTH & MEDICINE)">Biogen's FDA Pitch For MS Treatment Might Be Long Shot But It's Worth It, Execs Say The company breaks from tradition in attempt to get Tysabri back on the market.(HEALTH & MEDICINE)</a>
Close
Set up an RSS feed that alerts you when new articles from Investor's Business Daily are available.
Frequently asked questions about RSS feeds
Biogen's FDA Pitch For MS Treatment Might Be Long Shot But It's Worth It, Execs Say The company breaks from tradition in attempt to get Tysabri back on the market.(HEALTH & MEDICINE)
Byline: PETER BENESH
Officials at Biogen Idec know the company faces an uphill battle trying to get its multiple sclerosis drug, Tysabri, back to market.
But they insist their efforts are rooted in science -- not miracles.
Biogen has asked the Food and Drug Administration to reconsider the ban on the drug imposed Feb. 28.
The company withdrew the drug four months after its launch because three cases of a rare disease, progressive multifocal leukoencephalopathy (PML), came to light among Tysabri patients. One patient died.
Shares of Biogen and its Irish partner, Elan, plunged on the news. Biogen's stock fell 42% to 38.65 on Feb. 28. Elan declined 70% to 8 that same day. Neither stock has recovered.
Better Prepared
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- BIOGEN IDEC AND ELAN RELEASE TYSABRI SAFETY EVALUATION UPDATE.
- News wire article from: AsiaPulse News August 9, 2005 700+ words
...February 28, 2005, Biogen Idec and Elan announced...voluntarily suspended TYSABRI from the U.S...nervous system. Biogen Idec and Elan's...evaluation concerning TYSABRI and any possible...path forward for TYSABRI. Biogen Idec and Elan will...
- Biogen Idec and Elan Announce TYSABRI(R) Safety Evaluation Update.
- Press release article from: Business Wire August 9, 2005 700+ words
...February 28, 2005, Biogen Idec and Elan announced...voluntarily suspended TYSABRI from the U.S...nervous system. Biogen Idec and Elan's...evaluation concerning TYSABRI and any possible...path forward for TYSABRI. Biogen Idec and Elan will...
- Biogen Idec suspends Tysabri sales after patient death.
- Newspaper article from: North County Times (Escondido, CA) March 1, 2005 700+ words
...company, which developed Tysabri with Biogen Idec, has a facility in Sorrento Mesa. Biogen Idec suspended Tysabri sales as a "prudent" step...a Monday statement about Tysabri. Burt Adelman, Biogen Idec's executive vice...
- Sales likely to soar for new MS drug; Tysabri to be first drug for Biogen...
- Magazine article from: San Diego Business Journal Webb, Marion December 6, 2004 700+ words
...the demand we expect for Tysabri." By Dec. 31, Biogen Idec will have 500 employees...which will co-market Tysabri with Biogen Idec, agreed to continue...unpredictable neurological disease. biogen idec * Tysabri will be manufactured in its...
- Biogen Idec Plots its Positioning of Avonex and Tysabri to Maximize Revenues...
- Press release article from: PR Newswire September 25, 2006 700+ words
...the sales potential of Tysabri, it will be important for Biogen Idec to position the...treatment. This would allow Biogen Idec to start patients on Tysabri much sooner than if...Copaxone before considering Tysabri. "Biogen Idec will continue positioning...
- UPDATE 1-Will Biogen's Tysabri make it back to market?
- News wire article from: The America's Intelligence Wire May 12, 2005 700+ words
...marketing team. And at least for now, Biogen still produces Tysabri, albeit at a lower rate. Biogen co-markets Tysabri with Irish drugmaker Elan Corp...been filed to date. Since the Tysabri recall, Biogen and Elan have reviewed the medical...
- Biogen Idec and Elan announce update on Tysabri.
- News wire article from: Asia Africa Intelligence Wire March 3, 2005 700+ words
...patients receiving Tysabri monotherapy for MS...rheumatoid arthritis. Biogen Idec has not received...with Avonex alone. Biogen Idec and Elan will...investigators to evaluate Tysabri-treated patients...the marketing of Tysabri. Biogen Idec creates new...
- Biogen Idec Receives Approval for TYSABRI[R] High Titer Production.
- Press release article from: Business Wire April 16, 2009 700+ words
...multiple sclerosis (MS) drug TYSABRI([R]) (natalizumab). Biogen Idec received similar approval...in patients treated with TYSABRI in the post-marketing setting. TYSABRI is approved in more than 40 countries. Biogen Idec and Elan Corporation...
- Risky MS drug would aim at Crohn's: Tysabri, by BIogen Idec, has been linked to...
- News wire article from: News & Observer (Raleigh, NC) December 16, 2006 700+ words
...cautious about making revenue projections for Biogen if Tysabri is approved for Crohn's treatments. Michael...about commercialization," said Amy Brockelman of Biogen. Biogen pulled Tysabri off the market in February 2005 after the drug...
- Biogen sees Tysabri re-launch by June.
- News wire article from: The America's Intelligence Wire March 9, 2006 700+ words
...or Europe. Although Biogen is declining to estimate how much Tysabri could generate in sales...November 2004. The Tysabri news lifted Biogen shares $2.03, or...therapies. In addition, Biogen has proposed that Tysabri's prescribing information...